目的 探讨ABCB1 C3435T基因多态性与中国人群中他汀类药物疗效的关系。方法 计算机检索PubMed、Web of Science、Cochran Library、CNKI、WanFang Data、VIP。检索时间均从建库至2016年8月10日。采用非随机试验性研究的质量评价表进行质量评价。统计分析通过RevMan 5.3软件实现。结果 共纳入4个研究,630名研究对象。显性遗传模型TC+CC vs. TT 、隐性遗传模型CC vs. TT+TC 、加性遗传模型CC vs. TT 中ABCB1 C3435T基因多态性与中国人群中他汀对HDL-C、LDL-C、TC、TG影响的相关性均无统计学意义。结论 基于本研究结果,尚不能认为ABCB1 C3435T基因多态性与中国人群中他汀疗效有关联。期待今后针对中国人群开展更大样本、多中心、治疗随访时间较长、高质量的研究。
Abstract
OBJECTIVE To evaluate the association between ABCB1 C3435T polymorphism and statins effectiveness among Chinese population.METHODS Databases including PubMed, Web of Scien, Cochrance Library,CNKI,WanFang Data and VIP were searched to retrieve the relevant references from the start to August 2016. A quality assessment was performed using the Methodological Index for Non-Randomized Studies(MINORS)criteria. Meta-analysis,sensitivity analysis(RevMan 5.3)were all done.RESULTS A total of 4 studies were included for final Meta-analysis,involving 630 participants. The efficacy was evaluated by the change in TC (total cholesterol), TG(triglyceride), HDL-C(high density lipoprotein-cholesterol), and LDL-C(low density lipoprotein-cholesterol) after statin treatment. The pooled MDs were assessed for the dominant genetic model (CT+TT vs.CC), recessive genetic model (TT vs. CC+CT) and homozygote comparison (TT vs. CC).Overall,there was no statistically significant association for the four genetic models of statins effectiveness.CONCLUSION There is no association between ABCB1 C3435T polymorphism and statins effectiveness among Chinese population.
关键词
ABCB1 /
多态性 /
他汀药物 /
血脂水平 /
Meta分析 /
中国人群
{{custom_keyword}} /
Key words
ABCB1 /
polymorphism /
statin drug /
serum lipid level /
Meta-analysis /
Chinese
{{custom_keyword}} /
中图分类号：
R969
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1]BAIGENT C, KEECH A, KEARNEY P M, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J]. Lancet, 2005, 366 (9493): 1267-1278. [2]VERSCHUREN J J, TROMPET S, WESSELS J A, et al. A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? [J]. Eur Heart J, 2012, 33 (2): 165-175. [3]LEUSINK M, ONLAND-MORET N C, DE BAKKER P I, et al. Seventeen years of statin pharmacogenetics: a systematic review [J]. Pharmacogenomics, 2016, 17 (2): 163-180. [4]SIRTORI C R, MOMBELLI G, TRIOLO M, et al. Clinical response to statins: mechanism(s) of variable activity and adverse effects [J]. Ann Med, 2012, 44 (5): 419-432. [5]FROMM M F. Importance of P-glycoprotein for drug disposition in humans [J]. Eur J Clin Invest, 2003, 33(suppl 2):6-9. [6]KITZMILLER J P, BINKLEY P F, PANDEY S R, et al. Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes [J]. Discov Med, 2013, 16 (86): 45-51. [7]KAJINAMI K, BROUSSEAU M E, ORDOVAS J M, et al. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner [J]. Am J Cardiol, 2004, 93 (8): 1046-1050. [8]KESKITALO J E, KURKINEN K J, NEUVONENI P J, et al. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin [J]. Clin Pharmacol Ther, 2008, 84 (4): 457-461. [9]FIEGENBAUM M, DA S F R, VAN DER SAND C R, et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment [J]. Clin Pharmacol Ther, 2005, 78 (5): 551-558. [10]HOENIG M R, WALKER P J, GURNSEY C, et al. The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort [J]. J Clin Lipidol, 2011, 5 (2): 91-96. [11]SAACKA, BICZAK-KULETA, KACZMARCZYK M, et al. Possible association of ABCB1:c. 3435T>C polymorphism with high-density-lipoprotein-cholesterol response to statin treatment--a pilot study [J]. Bosn J Basic Med Sci, 2014, 14 (3): 144-149. [12]AMEYAW M M, REGATEIRO F, LI T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity [J]. Pharmacogenetics, 2001, 11 (3): 217-221. [13]LI Y, WANG Y, SUN J, et al. Distribution of the functional MDR1 C3435T polymorphism in the Han population of China [J]. Swiss Med Wkly, 2006, 136 (23-24): 377-382. [14]IEIRI I, TAKANE H, OTSUBO K. The MDR1 (ABCB1) gene polymorphism and its clinical implications [J]. Clin Pharmacokinet, 2004, 43 (9): 553-576. [15]SLIM K, NINI E, FORESTIER D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument [J]. ANZ J Surg, 2003, 73 (9): 712-716. [16]LIU Y W. Influence of the genetic polymorphisms of CYP3A4* 18A, CYP3A4*18B and MDR1 C3435T on Atorvastatin plasma concentration and Lipid-adjusting efficacy[D]. Fuzhou: Fujian Medical College, 2012. [17]GAO Y. Association study of CYP3A4*18B,CYP3A5*3 and MDRlC3435TGenetic Polymorphism with Lipid-lowering Efficacy of Atorvastatin[D]. Zhengzhou: Zhengzhou University, 2007. [18]SUN H F. Effect of CYP3A4,CYP3A5 and MDRl genetic polymorphisms on lipid-lowering efficacy of simvastatin in Chinesehyperlipidemie patients[D]. Zhengzhou: Zhengzhou University, 2006. [19]YANG Z Z. The Relationship Between Atorvastatin Related Metabolic Gene Polymorphisms And Lipid-lowering Effect with Stroke[D]. Fuzhou: Fujian Medical College, 2015. [20]SU J, XU H, YANG J, et al. ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a Meta-analysis [J]. Lipids Health Dis, 2015, 14:122. [21]KELLICK K A, BOTTORFF M, TOTH P P, et al. A clinician′s guide to statin drug-drug interactions [J]. J Clin Lipidol, 2014, 8(suppl 3):30-46.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家自然科学基金资助项目(81302843)
{{custom_fund}}
PDF(3115 KB)
